CDK6 and myeloproliferative disorder: Further support for a predominant kinase-independent role of CDK6 in JAK2-V617F+ disease stems from studies with human patient samples: primary mononuclear cells from the bone marrow of JAK2-V617F-positive MPN patients treated with palbociclib fail to show increased signs of apoptosis [25].